Listen
Reason for request
Modification of the wording of the indication: “Treatment of stable chronic heart failure with reduced systolic left ventricular function in addition to angiotensin-converting enzyme (ACE) inhibitors, and diuretics, and optionally cardiac glycosides”.
-
Clinical Benefit
| Substantial |
The actual benefit of these medicinal products is substantial. |
Clinical Added Value
| no clinical added value |
CARDENSIEL does not provide any improvement in actual benefit (IAB V) in the management of chronic stable heart failure with reduced systolic left ventricular function in addition to angiotensin-converting enzyme (ACE) inhibitors, and diuretics, and optionally cardiac glycosides. |
Documents
Contact Us
Évaluation des médicaments
